Investor Presentation • May 13, 2016
Investor Presentation
Open in ViewerOpens in native device viewer
May 13, 2016
| l S a e s |
E B I T |
N i t e n c o m e |
|
|---|---|---|---|
| F Y 2 0 1 5 |
€ 2 7 6 2 6 m , |
€ 3 9 5 8 m , |
€ 1 4 2 3 m , |
| G h t r o w t t c o n s a n c u r r e n c y |
9 % |
1 3 % |
2 1 % |
| G h t r o w l t t a c a a e s u r |
1 9 % |
2 5 % |
3 1 % |
Payout ratio: 21%
Fresenius Group sales
| S l a e s |
E B I T |
N i t e n c o m e |
|
|---|---|---|---|
| Q 1 2 0 1 6 |
€ 6 9 1 4 m , |
€ 9 5 9 m |
€ 3 6 2 m |
| G h t r o w t t o n n e n c s a c u r r c y |
7 % |
1 1 % |
2 3 % |
| G h t r o w l t t a c a a e s u r |
7 % |
1 3 % |
2 4 % |
| S l h t a e s g r o w t t c o n s a n c e n c u r r y |
6 % 8 % - |
|---|---|
| N i h t t e n c o m e g r o w t t c o n s a n c e n c u r r y |
8 % 2 % 1 - |
New mid-term financial goals
At comparable exchange rates
Without large acquisitions
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
May 13, 2016
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.